汉滩病毒是一种单负链RNA病毒,在我国主要引起以发热、出血、急性肾功能损害和免疫功能紊乱为主要特征的肾综合征出血热(HFRS),临床治疗尚无特效治疗药物,主要依靠灭活疫苗进行预防,但其诱导机体产生病毒中和抗体滴度较低,诱导细胞免疫...汉滩病毒是一种单负链RNA病毒,在我国主要引起以发热、出血、急性肾功能损害和免疫功能紊乱为主要特征的肾综合征出血热(HFRS),临床治疗尚无特效治疗药物,主要依靠灭活疫苗进行预防,但其诱导机体产生病毒中和抗体滴度较低,诱导细胞免疫反应能力差。病毒样颗粒(virus like particles,VLP)具有病毒天然蛋白成分和构象,但不含病毒核酸,是理想的候选疫苗。将表达汉滩病毒包膜糖蛋白Gn和Gc的M片段与含有表达汉滩病毒核蛋白的S片段的载体在哺乳动物细胞中共表达,包装出汉滩病毒VLP,对包装出的VLP进行初步纯化和生物学特性的鉴定。展开更多
Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and nece...Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and necessity to develop high-quality influenza vaccines in a safer, more efficient and economic way. The influenza subunit and VLP vaccines, taking the advantage of recombinant DNA technologies and expression system platforms, can be produced in such an ideal way. This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP). It would help to get insight into the current stage of influenza vaccines, and suggest the future design and development of novel influenza vaccines.展开更多
文摘汉滩病毒是一种单负链RNA病毒,在我国主要引起以发热、出血、急性肾功能损害和免疫功能紊乱为主要特征的肾综合征出血热(HFRS),临床治疗尚无特效治疗药物,主要依靠灭活疫苗进行预防,但其诱导机体产生病毒中和抗体滴度较低,诱导细胞免疫反应能力差。病毒样颗粒(virus like particles,VLP)具有病毒天然蛋白成分和构象,但不含病毒核酸,是理想的候选疫苗。将表达汉滩病毒包膜糖蛋白Gn和Gc的M片段与含有表达汉滩病毒核蛋白的S片段的载体在哺乳动物细胞中共表达,包装出汉滩病毒VLP,对包装出的VLP进行初步纯化和生物学特性的鉴定。
基金The Knowledge Innovation Program of the Chinese Academy of Sciences (Grant No. KSCX2-EW-G-8)
文摘Influenza virus is a continuous and severe global threat to mankind. The continuously re-emerging disease gives rise to thousands of deaths and enormous economic losses each year, which emphasizes the urgency and necessity to develop high-quality influenza vaccines in a safer, more efficient and economic way. The influenza subunit and VLP vaccines, taking the advantage of recombinant DNA technologies and expression system platforms, can be produced in such an ideal way. This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP). It would help to get insight into the current stage of influenza vaccines, and suggest the future design and development of novel influenza vaccines.
